tiprankstipranks

Deciphera downgraded to Neutral from Buy at Guggenheim

Guggenheim downgraded Deciphera to Neutral from Buy with a $26 price target after the company entered into a definitive merger agreement with Ono Pharmaceutical for Ono to acquire Deciphera for $25.60 per share through a tender offer.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue